PREDICTT Clinical Trial: Y90 Microsphere Therapy for Liver Tumors
This study is looking at a treatment called Y90 Microsphere Therapy for people with liver tumors that cannot be removed by surgery. This therapy uses a device called the TriNav Infusion System to deliver tiny radioactive beads directly to the tumor. Researchers want to see if this system changes how much of the treatment reaches the tumor compared to healthy liver tissue, by looking at CT scans. They will also check the safety of the TriNav catheter. You might be able to join if you are over 18, have liver tumors that can't be surgically removed, and are eligible for Y90-radioembolization treatment. The study aims to enroll 20 participants, but its current status is unclear.
- Study design
- This is a single-arm study, meaning all 20 participants will receive the same intervention. The phase of the study is not specified.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety and any side effects will be monitored through study completion, which is an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
PREDICTT Clinical Trial: Prospective Evaluation Of Pressure-Enabled Delivery And Alterations In CT-Based Tumor-To-Normal Liver Ratio And Tumor Dose Using The Trinav Infusion System
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Peiman Habibollahi, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
- S. Cheenu Kappadath, PHD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and Adverse Events (AEs)Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0